Project Grant R21CA317474
Award Date 8/10/26
Completion Date 7/31/28
Dollars Obligated $441K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Beckman Research Institute of the City of Hope $2,486,215 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing R01CA313241) to conduct mutational epidemiology research on childhood acute lymphoblastic leukemia in California. The research combines tumor mutation pattern analysis with epidemiological methods to identify environmental causes of childhood ALL. The project leverages the...
- The National Cancer Institute awarded $321,097 to Baylor College of Medicine on July 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and pilot-test a telehealth-delivered cognitive-behavioral therapy protocol for insomnia in children receiving maintenance therapy for acute lymphoblastic leukemia. The award funds the Resolving Sleep Troubles in Childhood Leukemia (REST) project, which adapts evidence-based cognitive-behavioral therapy for pediatric...
- The National Cancer Institute, National Institutes of Health, awarded a $7.482 million Cooperative Agreement to Baylor College of Medicine on September 23, 2025, under the Cancer Centers Support Grants program (CFDA 93.397) to reduce ethnic disparities in acute lymphoblastic leukemia among Latino children and adolescents by identifying biological and social determinants of health factors that drive adverse outcomes. The award funds four research projects addressing hepatotoxicity and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Baylor College of Medicine $321,000 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize germline and somatic genetic variants in Langerhans cell histiocytosis pathogenesis. The research investigates inherited and acquired genetic factors contributing to LCH risk and adverse outcomes. LCH is an inflammatory myeloid neoplasia characterized by pathogenic...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Baylor College of Medicine a $882,470 Research Specialist (Clinician Scientist) Award under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2030. The award supports clinical leadership and trial development services focused on pediatric and adolescent cancer patients with hematologic malignancies. The primary deliverables include establishment and facilitation of a...
- The National Institutes of Health National Cancer Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $274,676 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support translational research on inherited genetic variation in B-cell acute lymphoblastic leukemia predisposition. The funded research dissects the role of common and rare risk variants in the IKZF1 locus, which encodes a key regulator of B-cell...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $522,196 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate non-canonical BRAF mutations in acute myeloid leukemia development and therapeutic response. The recipient will conduct research to delineate how BRAF mutations contribute to leukemogenesis, disease phenotype, and therapeutic resistance in AML patients who exhibit dismal survival outcomes regardless of treatment...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $350,860 on September 1, 2026, through a Cooperative Agreement (UH2CA312695) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to implement exome capture-based RNA sequencing for real-time clinical risk stratification in pediatric B-cell acute lymphoblastic leukemia (B-ALL) treatment. The recipient will establish centralized diagnostic RNA sequencing-based molecular classification across three...
- The National Cancer Institute (NCI) awarded a $483,110 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope to conduct research on the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL). The 5-year project aims to systematically dissect the mechanisms by which PAX5 mutations, which occur in over 10% of B-ALL cases, contribute to disease initiation and progression. The research will use orthogonal...